Exploring the potential of Scabiosa columbaria in Alzheimer's disease treatment: An in silico approach

被引:1
|
作者
Irsal, Riyan A. P. [1 ,2 ]
Gholam, Gusnia M. [2 ,3 ]
Dwicesaria, Maheswari A. [2 ]
Mansyah, Tiyara F. [2 ]
Chairunisa, Fernanda [4 ]
机构
[1] Biomatics, Bogor, West Java, Indonesia
[2] Bogor Agr Univ, Fac Math & Nat Sci, Dept Biochem, Bogor, Indonesia
[3] Indonesian Inst Bioinformat, Bioinformat Res Ctr, Malang, Indonesia
[4] Univ Nasional, Dept Biol, Pasar Minggu 12520, South Jakarta, Indonesia
来源
关键词
Acetylcholinesterase; BACE1; Natural anti-AD agent; TACE; YASARA structure; INHIBITORS; DRUG; MECHANISMS; LINALOOL; DESIGN;
D O I
10.1016/j.jtumed.2024.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Alzheimer's disease (AD) is posing an increasing global threat and currently lacks effective treatments. Therefore, this study was aimed at exploring phytochemicals in Scabiosa columbaria ( S. columbaria) ) as inhibitors of acetylcholinesterase (AChE), b-site APP cleavage enzyme 1 (BACE1), and TNF-a a converting enzyme (TACE) in AD. S. columbaria contains various bioactive compounds, such as chlorogenic acid, linalool, and catechins, which are known for their detoxification properties, capacity to resist and manage harmful moisture buildup, and therapeutic roles in COVID-19. Several studies have also shown that S. columbaria extract has strong antioxidant activity, and may potentially decrease neuroinflammation in AD. Therefore, this study investigated the interactions between S. columbaria phytochemicals and key enzymes associated with AD, thus providing opportunities for the development of new therapeutic candidates. Methods: A total of 27 phytochemicals were evaluated for their inhibitory activity against AChE, BACE1, and TACE with YASARA Structure. ADMET profiles and toxicity were assessed. The top candidate compounds underwent 100 ns MD simulations. Results: All ligands met Lipinski's rule and showed low toxicity. Catechins, compared with the known drug galantamine, showed higher inhibitory activity and interacted with additional active sites on AChE, thus suggesting potentially higher efficacy. Moreover, chlorogenic acid showed stronger inhibitory activity against TACE than the control drug (aryl-sulfonamide), thereby suggesting a different mechanism of action. MD simulation revealed that the formed complexes had good stability. However, further exploration is necessary. Conclusion: S. columbaria derivative compounds are promising drug candidates because of their properties, including the affinity of chlorogenic acid toward TACE and hydrogen bond enhancing ligand-receptor interactions. MD simulation indicated stable ligand-protein complexes, and the radius of gyration and MM-PBSA calculations revealed favorable binding and interaction energies. Our findings demonstrate the identified compounds' potential for further drug development.
引用
收藏
页码:947 / 960
页数:14
相关论文
共 50 条
  • [41] A Drug Repositioning Approach Reveals Ergotamine May Be a Potential Drug for the Treatment of Alzheimer's Disease
    Wang, Qiuchen
    Fu, Mengjie
    Gao, Lihui
    Yuan, Xin
    Wang, Ju
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 (04) : 1355 - 1366
  • [42] Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease
    Crook, Harry
    Edison, Paul
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S357 - S370
  • [43] The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease
    Anderson, Chloe
    Bucholc, Magda
    Mcclean, Paula L.
    Zhang, Shu-Dong
    BIOMOLECULES, 2024, 14 (01)
  • [44] In Silico Identification of a Potential TNF-Alpha Binder Using a Structural Similarity: A Potential Drug Repurposing Approach to the Management of Alzheimer's Disease
    Tettevi, Edward Jenner
    Kuevi, Deryl Nii Okantey
    Sumabe, Balagra Kasim
    Simpong, David Larbi
    Maina, Mahmoud B.
    Dongdem, Julius T.
    Osei-Atweneboana, Mike Y.
    Ocloo, Augustine
    BIOMED RESEARCH INTERNATIONAL, 2024, 2024
  • [45] Exploring exosomes to provide evidence for the treatment and prediction of Alzheimer's disease
    Quan, Xiangyu
    Ma, Xueting
    Li, Guodong
    Fu, Ueqi
    Li, Jiangtao
    Zeng, Linlin
    BIOCELL, 2023, 47 (10) : 2176 - 2176
  • [46] Exploring facile synthesis and cholinesterase inhibiting potential of heteroaryl substituted imidazole derivatives for the treatment of Alzheimer's disease
    Chaudhry, Faryal
    Munir, Rubina
    Ashraf, Muhammad
    Mehr-un-Nisa
    Huma, Rahila
    Malik, Nayab
    Hussain, Safdar
    Munawar, Munawar Ali
    Khan, Misbahul Ain
    ARABIAN JOURNAL OF CHEMISTRY, 2023, 16 (01)
  • [47] Identify Compounds' Target Against Alzheimer's Disease Based on In-Silico Approach
    Hu, Yan
    Zhou, Guangya
    Zhang, Chi
    Zhang, Mengying
    Chen, Qin
    Zheng, Linfeng
    Niu, Bing
    CURRENT ALZHEIMER RESEARCH, 2019, 16 (03) : 193 - 208
  • [48] A Potential Role for the Ketogenic Diet in Alzheimer's Disease Treatment: Exploring Pre-Clinical and Clinical Evidence
    Oliveira, Tadeu P. D.
    Morais, Ana L. B.
    dos Reis, Pedro L. B.
    Palotas, Andras
    Vieira, Luciene B.
    METABOLITES, 2024, 14 (01)
  • [49] Disease-modifying treatment for Alzheimer's disease: the neurotrophic approach
    Bossi, L
    ALZHEIMERS REPORTS, 1998, 1 : S29 - S30
  • [50] Exploring Biomarkers for Alzheimer's Disease
    Sharma, Neeti
    Singh, Anshika Nikita
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (07) : KE1 - KE6